GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codexis Inc (FRA:4QK) » Definitions » Total Liabilities

Codexis (FRA:4QK) Total Liabilities : €78.39 Mil (As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Codexis Total Liabilities?

Codexis's Total Liabilities for the quarter that ended in Dec. 2024 was €78.39 Mil.

Codexis's quarterly Total Liabilities increased from Jun. 2024 (€65.55 Mil) to Sep. 2024 (€67.38 Mil) and increased from Sep. 2024 (€67.38 Mil) to Dec. 2024 (€78.39 Mil).

Codexis's annual Total Liabilities declined from Dec. 2022 (€99.68 Mil) to Dec. 2023 (€45.80 Mil) but then increased from Dec. 2023 (€45.80 Mil) to Dec. 2024 (€78.39 Mil).


Codexis Total Liabilities Historical Data

The historical data trend for Codexis's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codexis Total Liabilities Chart

Codexis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.37 72.56 99.68 45.80 78.39

Codexis Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.80 64.67 65.55 67.38 78.39

Codexis Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Codexis's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=22.584+(54.5+1.21
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.096+0+0)
=78.39

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=142.306-63.915
=78.39

Codexis's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=22.584+(54.5+1.21
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.096+0+0)
=78.39

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=142.306-63.915
=78.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Codexis Total Liabilities Related Terms

Thank you for viewing the detailed overview of Codexis's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Codexis Business Description

Traded in Other Exchanges
Address
200 Penobscot Drive, Redwood City, CA, USA, 94063
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Codexis Headlines

No Headlines